The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis-Reference-Cited by-同舟云学术

The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis

Published:2021-05 Issue: Volume:104 Page:106335
ISSN:1551-7144
Container-title:Contemporary Clinical Trials
language:en
Short-container-title:Contemporary Clinical Trials

Author:

Abdelmalek Manal F.,Charles Edgar D.,Sanyal Arun J.,Harrison Stephen A.,Neuschwander-Tetri Brent A.,Goodman Zachary,Ehman Richard A.,Karsdal Morten,Nakajima Atsushi,Du Shuyan,Tirucherai Giridhar S.,Klinger George H.,Mora Johanna,Yamaguchi Masayuki,Shevell Diane E.,Loomba Rohit

Funder

Bristol-Myers Squibb Co

Publisher

Elsevier BV

Subject

Pharmacology (medical),General Medicine

Reference28 articles.

1. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases;Chalasani;Hepatology,2018

2. Global epidemiology of nonalcoholic fatty liver disease - meta-analytic assessment of prevalence, incidence, and outcomes;Younossi;Hepatology,2016

3. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis;Taylor;Gastroenterology,2020

4. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis;Promrat;Hepatology,2010

5. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis;Vilar-Gomez;Gastroenterology,2015

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities;European Journal of Medicinal Chemistry;2024-11

2. Endocrine fibroblast growth factors in domestic animals;Domestic Animal Endocrinology;2024-10

3. Deciphering the therapeutic efficacy of FGF19 and FGF21 in NAFLD: A comparative genomic and metabolic analysis;Food Bioscience;2024-08

4. Development of Zalfermin, a Long-Acting Proteolytically Stabilized FGF21 Analog;Journal of Medicinal Chemistry;2024-07-16

5. The endocrine FGFs axis: A systemic anti-fibrotic response that could prevent pulmonary fibrogenesis?;Pharmacology & Therapeutics;2024-07